Neurocrine Biosciences
NBIX
NBIX
483 hedge funds and large institutions have $9.2B invested in Neurocrine Biosciences in 2023 Q1 according to their latest regulatory filings, with 57 funds opening new positions, 198 increasing their positions, 163 reducing their positions, and 86 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
483
Holders Change
-43
Holders Change %
-8.17%
% of All Funds
7.73%
Holding in Top 10
7
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-22.22%
% of All Funds
0.11%
New
57
Increased
198
Reduced
163
Closed
86
Calls
$17.5M
Puts
$30.2M
Net Calls
-$12.7M
Net Calls Change
-$46.8M
Top Buyers
| 1 |
BlackRock
New York
|
+$84.9M |
| 2 |
B
Braidwell
Stamford,
Connecticut
|
+$77.6M |
| 3 |
AC
Armistice Capital
New York
|
+$70M |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$37.2M |
| 5 |
Primecap Management
Pasadena,
California
|
+$37.1M |
Top Sellers
| 1 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$97.6M |
| 2 |
Invesco
Atlanta,
Georgia
|
-$86.1M |
| 3 |
1832 Asset Management
Toronto,
Ontario, Canada
|
-$82.6M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$76.3M |
| 5 |
Janus Henderson Group
London,
United Kingdom
|
-$42.6M |
